Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

Brian G. Feagan(Western University), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Ian Beales(University of East Anglia), Séverine Vermeire(KU Leuven), Frank Seibold(Lindenhofspital), Ursula Seidler(Medizinische Hochschule Hannover), Toshifumi Hibi∥(Kitasato Institute Hospital), Rajiv Mehta(Amrita Institute of Medical Sciences and Research Centre), William J. Sandborn(University of San Diego), Rafał Filip(University of Rzeszów), Mamoru Watanabe(The University of Tokyo), Silvio Danese(IRCCS Ospedale San Raffaele), R. Besuyen(Galapagos (Belgium)), Sally Zhao(Gilead Sciences (United States)), Edward V. Loftus(Mayo Clinic), Gerhard Rogler(University Hospital of Zurich), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Radosław Kempiński(Wroclaw Medical University), Ihor Hospodarskyy(I.Horbachevsky Ternopil National Medical University), Ronald Fogel(Henry Ford Health System), Chantal Tasset(Galapagos (Belgium)), Xiaopeng Liu(Chinese Academy of Sciences), Hyo Jong Kim(Kyung Hee University), Chia‐Hsiang Hsueh(Gilead Sciences (United States)), John McNally(Gilead Sciences (United States)), Sandeep Nijhawan(SMS Medical College), Timothy E. Ritter(Unknown), Chohee Yun(Gilead Sciences (United States))
The Lancet
June 1, 2021
Cited by 452


Related Papers